California

Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR

SAN FRANCISCO, July 20, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and…
Continue Reading »
California

OMCL CLASS ACTION ALERT: Hagens Berman Alerts Omnicell (OMCL) Investors to Class Action, Encourages Investors Who Suffered $50,000+ Losses to Contact the Firm

SAN FRANCISCO, July 19, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Omnicell, Inc. (NASDAQ: OMCL) to the securities class action, Bursick v. Omnicell, Inc. et al., No.…
Continue Reading »
California

Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, July 19, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it…
Continue Reading »